CORRECTION

Open Access

Correction: The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma



Mei Feng^{1†}, Hao Xu^{1†}, Wenyuan Zhou² and Yisheng Pan^{1*}

Correction: J Exp Clin Cancer Res 42:44 (2023) https://doi.org/10.1186/s13046-023-02615-2

Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 3; specifically in Fig. 3C and D. The image for the NCI-N87 cell line in Fig. 3C (row 1) was mistakenly included. Consequently, the corresponding statistical analysis for NCI-N87 in Fig. 3D also needs to be corrected.

The corrected figure is given below. The correction does not have any effect on the results or conclusions of the paper.

The original article [1] has been corrected.

[†]Mei Feng and Hao Xu contributed equally to this work.

The online version of the original article can be found at https://doi. org/10.1186/s13046-023-02615-2.

*Correspondence: Yisheng Pan yisheng_pan@126.com ¹Division of General Surgery, Peking University First Hospital, Peking University, No. 8, Xi Shiku Street, Beijing 100034, China ²Department of Nuclear Medicine, 2NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, Beijing 100142, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Incorrect Figure 3.

Fig. 3 Cellular effects of the combination of ABE and JQ1 on in vitro GC cell models. **A** Representative synergy models of ABE and JQ1 across GC cell lines. **B** Bar plot of the average and maximum of synergy score among 13 GC cell lines. score > 10 indicates synergy. score < -10 indicates antagonism. **C** Crystal violet staining of colonies from six representative cell lines during 2 weeks with the indicated treatment of DMSO, ABE (100nM), JQ1(100nM), and ABE (100nM) + JQ1 (nM). **D** Quantification of the colonies area using imageJ software. The data are presented as the mean ± SEM of three replicates. **E** Representative Cell cycle plots of different GC cell lines treated with DMSO, ABE (1000nM), JQ1(500nM), or ABE (1000nM) + JQ1 (500nM) for 48 h as examined by flow cytometry analyses. **F** Representative histograms of the ratio of G1, S, and G2 phase of GC cell lines with different treatments



Fig. 3 Cellular effects of the combination of ABE and JQ1 on in vitro GC cell models. A Representative synergy models of ABE and JQ1 across GC cell lines. B Bar plot of the average and maximum of synergy score among 13 GC cell lines. score > 10 indicates synergy. score < -10 indicates antagonism. C Crystal violet staining of colonies from six representative cell lines during 2 weeks with the indicated treatment of DMSO, ABE (100nM), JQ1(100nM), and ABE (100nM) + JQ1 (nM). D Quantification of the colonies area using imageJ software. The data are presented as the mean ± SEM of three replicates. E Representative Cell cycle plots of different GC cell lines treated with DMSO, ABE (1000nM), JQ1(500nM), or ABE (1000nM) + JQ1(500nM) for 48 h as examined by flow cytometry analyses. F Representative histograms of the ratio of G1, S, and G2 phase of GC cell lines with different treatments

Published online: 20 July 2024

Reference

 Feng M, Xu H, Zhou W, et al. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023;42:44. https://doi.org/10.1186/s13046-023-02615-2.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.